Our lab is dedicated to optimizing sickle cell disease (SCD) care globally by researching brain and pain complications. We focus on improving current care protocols, identifying genetic modifiers of pain and cerebrovascular disease, and exploring innovative strategies to enhance quality of life and development. Our research encompasses genetic studies through the INHERENT network, non-opioid pain management, brain health challenges, and the impact of social determinants on health outcomes. Key projects include using ketamine for pain relief, early intervention for academic challenges, and socioeconomic studies related to SCD. We are also committed to improving SCD care in resource-limited settings and fostering a diverse, equitable, and inclusive research environment. Our global health initiatives aim to establish sustainable care programs, while our diversity efforts focus on creating a just and inclusive culture. By addressing both clinical and social aspects of SCD, our lab strives to make a meaningful impact on patient outcomes and advance scientific understanding of the disease.